A System for the Pharmacological Application of Metformin in Cardiac Remodeling

A German Patent entitled “A System for the Pharmacological Application of Metformin in Cardiac Remodeling” (Patent No. 202022100355), IPC: C12N 1/38 is granted to Dr. Salma Naqvi, Assistant Professor, Pharmacology, GMU Ajman, on 8th March, 2022.

Abstract:

Metformin, a biguanide, is a well-established, potential antidiabetic drug, which is cost-effective and has a safer adverse effects profile. Studies have reported that Metformin has favourable effects on left ventricular functions. At cellular level, it produces both AMP activated kinase (AMPK) dependent and independent effects. At the systemic level, it improves endothelial function, protects from oxidative stress and inflammation, and from the negative effect of angiotensin II. On the myocardium it attenuates ischemia reperfusion injury and prevents adverse remodeling induced by humoral and hemodynamic factors. It is however, unknown whether metformin improves cardiac remodelling in a long term post MI remodelling model. Our study revealed the cardioprotective effects of metformin on NaCl- induced cardiac remodelling in rats.